Galectin-3 and prediction of therapeutic response to renal sympathetic denervation

Schwerg, Marius; Eilers, Björn; Wienecke, Anja; Baumann, Gert; Laule, Michael; Knebel, Fabian; Stangl, Karl; Stangl, Verena

doi:10.3109/10641963.2016.1148157

Cited by 3 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with resistant hypertension undergoing renal sympathetic denervation, baseline serum galectin levels were significantly increased in responders compared with non-responders, and no significant changes in galectin-3 levels were observed during the follow-up period. These results indicated that galectin-3 may assist in identifying patients suitable for renal denervation ( 112 ).…”

Section: Galectin-3 and Renal Diseasementioning

confidence: 85%

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

Galectin-3 is a member of the galectin family, which are β-galactoside-binding lectins with ≥1 evolutionary conserved carbohydrate-recognition domain. It binds proteins in a carbohydrate-dependent and -independent manner. Galectin-3 is predominantly located in the cytoplasm; however, it shuttles into the nucleus and is secreted onto the cell surface and into biological fluids including serum and urine. It serves important functions in numerous biological activities including cell growth, apoptosis, pre-mRNA splicing, differentiation, transformation, angiogenesis, inflammation, fibrosis and host defense. Numerous previous studies have indicated that galectin-3 may be used as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease and cancer. With emerging evidence to support the function and application of galectin-3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin-3 in associated diseases.

show abstract

Section: Galectin-3 and Renal Diseasementioning

confidence: 85%

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The general characteristics and patient demographics of these studies are summarized in Table 1 . Due to the lack of valid data, the remaining 33 studies were used only for qualitative analysis, 12 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 and their basic characteristics are summarized in Table S2 .…”

Section: Resultsmentioning

confidence: 99%

“…Thirteen studies qualitatively characterized the relationship between biomarkers and the BP‐lowering effect of RDN, 33 , 36 , 38 , 39 , 42 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 these studies were mainly for qualitative analysis due to the lack of valid data. Several biomarkers that reflect increased sympathetic activity, such as plasma aldosterone concentration 39 and protein levels of norepinephrine 42 were reported to be associated with a more pronounced RDN antihypertensive effect.…”

Section: Resultsmentioning

confidence: 99%

“…Several biomarkers that reflect increased sympathetic activity, such as plasma aldosterone concentration 39 and protein levels of norepinephrine 42 were reported to be associated with a more pronounced RDN antihypertensive effect. Other biomarkers, including lower numbers of activated double‐negative T cells, lower total T CD8+, CD4+, and naïve T CD8+ cells, 55 , 56 lower levels of RANTES (a soluble proinflammatory chemokine), 56 higher sFlt‐1 (soluble fms‐like tyrosine kinase‐1), 38 higher levels of endothelial adhesion molecules (ICAM‐1 [intercellular cell adhesion molecule‐1], VCAM‐1 [vascular cell adhesion molecule‐1]), 36 , 38 higher Gal‐3 (galectin‐3) levels, 52 higher CRP (C‐reactive protein), 33 higher IL‐6 (interleukin‐6), 53 higher baseline midregional proadrenomedullin, 54 lower skin sodium content, 58 and higher vitamin D concentrations, 51 , 57 were reported possibly associated with the antihypertensive effect of RDN. The risk of bias was low or moderate in most of the included studies, except for 1 study with a high risk of bias 39 (Table S4 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Patient‐Specific Factors Predicting Renal Denervation Response in Patients With Hypertension: A Systematic Review and Meta‐Analysis

Hu,

Liao,

Wang

et al. 2024

JAHA

View full text Add to dashboard Cite

Background The accurate selection of patients likely to respond to renal denervation (RDN) is crucial for optimizing treatment outcomes in patients with hypertension. This systematic review was designed to evaluate patient‐specific factors predicting the RDN response. Methods and Results We focused on individuals with hypertension who underwent RDN. Patients were categorized based on their baseline characteristics. The primary outcome was blood pressure (BP) reduction after RDN. Both randomized controlled trials and nonrandomized studies were included. We assessed the risk of bias using corresponding tools and further employed the Grading of Recommendations Assessment, Development, and Evaluation approach to assess the overall quality of evidence. A total of 50 studies were ultimately included in this systematic review, among which 17 studies were for meta‐analysis. Higher baseline heart rate and lower pulse wave velocity were shown to be associated with significant antihypertensive efficacy of RDN on 24‐hour systolic BP reduction (weighted mean difference, −4.05 [95% CI, −7.33 to −0.77]; weighted mean difference, −7.20 [95% CI, −9.79 to −4.62], respectively). In addition, based on qualitative analysis, higher baseline BP, orthostatic hypertension, impaired baroreflex sensitivity, and several biomarkers are also reported to be associated with significant BP reduction after RDN. Conclusions In patients with hypertension treated with the RDN, higher heart rate, and lower pulse wave velocity were associated with significant BP reduction after RDN. Other factors, including higher baseline BP, hypertensive patients with orthostatic hypertension, BP variability, impaired cardiac baroreflex sensitivity, and some biomarkers are also reported to be associated with a better BP response to RDN.

show abstract

“…Another study suggested that patients with lower central pulse pressure (below the median 55 mmHg) manifested a significantly greater BP reduction assessed by either office BP or 24 h-ABPM after RDN compared to those with higher central pulse pressure, indicating a lower degree of damage of the arterial vasculature [55]. Other biomarkers, such as galectin-3 [56], intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and soluble receptor fms-like tyrosine kinase-1 (sFLT-1) [57], leading to stiffness or endothelial dysfunction, are also proposed to be predictive indicators of responders for RDN at baseline.…”

Section: Vascular Stiffness and Isolated Systolic Hypertensionmentioning

confidence: 99%

Present Evidence of Determinants to Predict the Efficacy of Renal Denervation

Zhou

Chen

et al. 2022

International Journal of Hypertension

View full text Add to dashboard Cite

Sympathetic overactivation is one of the main contributors to development and progress of hypertension. Renal denervation (RDN) has been evidenced by series of clinical trials for its efficacy and safety to treat overactivated sympathetic nervous system induced diseases. However, the results were inconsistent and not all patients benefited from RDN. Appropriate patient selection and intraoperative factors to improve the efficacy of RDN need to be solved urgently. Over the decade, research studies on the correlations between indicators and the antihypertensive effects have been conducted and made a fairly well progress. Herein, we comprehensively reviewed the research studies on how to make RDN more predictable or improve the efficacy of RDN and summarized these potential indicators or devices which might be applied in clinical settings.

show abstract

Galectin-3 and prediction of therapeutic response to renal sympathetic denervation

Cited by 3 publications

References 32 publications

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Patient‐Specific Factors Predicting Renal Denervation Response in Patients With Hypertension: A Systematic Review and Meta‐Analysis

Present Evidence of Determinants to Predict the Efficacy of Renal Denervation

Contact Info

Product

Resources

About